Camurus’ Interim Report Second Quarter 2022
“For the first time and ahead of plan, Camurus entered profitability in the second quarter” Second quarter summary April - June · Total revenues amounted to SEK 227 (138) million, an increase of 64% (55% at CER[1]),whereof product sales were SEK 225 (137) million, an increase of 65% (56% at CER) · Operating result was SEK 7 (-60) million, an increase of SEK 67 million · Cash position at the end of the quarter was SEK 428 (422) million · Number of patients treated with Buvidal[®] at the end of the quarter estimated to around 30,000 · Buvidal 160mg launched in